<DOC>
	<DOCNO>NCT01927198</DOCNO>
	<brief_summary>This study ass serum uric acid lower effect safety 3 dose level RDEA3170 compare placebo subject gout .</brief_summary>
	<brief_title>RDEA3170 Monotherapy Subjects With Gout</brief_title>
	<detailed_description>This monotherapy study initial Phase 2 study RDEA3170 design compare safety efficacy multiple dose level RDEA3170 placebo give 24 week subject gout . The placebo control RDEA3170 include study minimize bias study assessment monitoring . Further , accomplish goal understand safety profile RDEA3170 , important compare RDEA3170 monotherapy placebo least 24 week .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<criteria>Subject meet diagnosis gout per American Rheumatism Association Criteria Classification Acute Arthritis Primary Gout . Subject serum urate level ≥ 6.5 mg/dL ≤ 10.0 mg/dL Screening Period . Subject body mass index &lt; 40 kg/m2 . Subject pregnant breastfeeding . Subject consume 14 drink alcohol per week ( eg , 1 drink = 5 oz [ 150 mL ] wine , 12 oz [ 360 mL ] beer , 1.5 oz [ 45 mL ] hard liquor ) . Subject history suspicion kidney stone . Subject history suspicion drug abuse within past 5 year . Subject history symptomatic myositis/myopathy rhabdomyolysis . Subject know suspected human immunodeficiency virus infection . Subject positive test active hepatitis B hepatitis C infection . Subject history malignancy within previous 5 year exception nonmelanoma skin cancer treat evidence recurrence , treat cervical dysplasia , treat situ Grade 1 cervical cancer . Subject within last 12 month : unstable angina , New York Heart Association class III IV heart failure , myocardial infarction , stroke , deep venous thrombosis ; subject currently receive anticoagulant . Subject QT interval correct heart rate accord Fridericia 's formula &gt; 450 msec Screening Period , confirm repeat assessment . Subject uncontrolled hypertension . Subject estimate creatinine clearance &lt; 60 mL/min . Subject alkaline phosphatase &gt; 2.0 x upper limit normal Screening Period . Subject active liver disease impair hepatic function . Subject receive chronic treatment 325 mg salicylate per day . Subject medical condition require may require systemic immunosuppressive ( eg , chronic lowdose oral prednisone ) immunomodulatory treatment . Subject unable take colchicine gout flare prophylaxis . Subject receive strong moderate CYP3A inhibitor , pglycoprotein inhibitor , digoxin . Subject receive strong enzyme induce drug product ( eg , rifampin , rifabutin , phenytoin , phenobarbital , St. John 's Wort ) within 2 month prior Day 1 refuse refrain take medication end study . Subject receive investigational therapy within 30 day 5 halflives ( whichever longer ) prior Screening Period . Subject medical psychological condition , opinion Investigator and/or Medical Monitor , might create undue risk subject interfere subject 's ability comply protocol requirement , complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>